

In the Claims

Please cancel Claims 2-4 and 15.

Please also cancel Claims 1, 5, 6, 8, and 14.

Please add new Claims 34-38 as follows:

om 34. A substantially non-irritating pharmaceutical formulation for topical and/or transdermal administration of the agent 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, which formulation comprises:

B 9 B B 889 p 1 (a) a therapeutically effective amount of 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; and

B 889 B B p 1 (b) a pharmaceutically acceptable vehicle for said 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, which vehicle comprises isostearic acid in an amount of about 3 percent to about 45 percent by weight based on the total weight of said formulation, said formulation being further characterized in that, when tested according to the hairless mouse skin model the formulation provides a penetration of the agent of at least about 10 percent of the total amount of the agent contained in the formulation in 24 hours.

C B B 35. A formulation according to claim 34 wherein said 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine is present in an amount of about 0.5 percent to about 9 percent by weight based on the total weight of said formulation.

3 36. A formulation according to claim 34 in the form of a cream, comprising an oil phase and a water phase in admixture, said oil phase comprising:

p 1 B 889 B (a) said 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine;

p 1 (b) said isostearic acid;

p 1 B (c) one or more emollients present in a total amount of about 5 percent to about 30 percent by weight based on the total weight of said formulation; and

4-3